See the DrugPatentWatch profile for Alemtuzumab
Has the alemtuzumab patent term been extended, and what does “term extension” usually mean?
Patent “term extension” can refer to a few different legal mechanisms, depending on the country, including extending the effective time a patent can be used in light of regulatory delays or extending exclusivity periods under specific statutes. For biologics like alemtuzumab, extension questions often come up alongside related exclusivity protections (such as regulatory and marketing exclusivity) and ongoing patent estates rather than a single blanket extension.
No specific patent-term extension details (jurisdiction, patent numbers, or dates) are provided in the available information, so it is not possible to confirm whether alemtuzumab’s term was extended or to identify the exact extended end date.
Which jurisdiction matters most for alemtuzumab patent term extension?
The rules and terminology vary heavily by jurisdiction:
- In the US, the most common “extension” concept is Patent Term Adjustment (PTA) and Patent Term Extension (PTE) frameworks, but whether either applies depends on the exact patent, prosecution history, and regulatory timelines.
- In the EU, extension-like concepts often track with supplementary protection certificates (SPCs) or similar regulatory delay compensation mechanisms, again depending on the specific patent/patentable subject matter and regulatory authorization details.
Without jurisdiction and patent identifiers, the claim cannot be grounded to a concrete extension mechanism for alemtuzumab.
What are the practical reasons companies pursue an extension for alemtuzumab?
Companies typically pursue additional time to protect revenue streams when:
- The drug’s market authorization took substantial time.
- Related patents in the “estate” are set to expire and coverage gaps could allow competitors earlier market entry.
- Enforcement relies on maintaining exclusivity while switching to next-generation formulations, lines of therapy, or new indications.
If you are looking for a specific company’s strategy (or whether competitors are “waiting out” a fixed date), you’d need the relevant country and patent/public record.
How to find the exact extended expiration date for alemtuzumab
To determine whether an alemtuzumab patent term was extended (and to what date), you generally need:
1. Country (US, EU, UK, etc.).
2. The specific patent number(s).
3. Whether the extension type is PTA/PTE (US) or SPC (EU), or another statutory adjustment.
4. The marketing authorization date(s) that anchor the extension calculation (the “regulatory delay” component).
5. Any subsequent litigation or patent invalidation rulings that change enforceability.
With that information, you can compute or verify the extended expiration date from the official patent and regulatory records.
Is this about patent extension or biological exclusivity (biosimilar entry)?
A common point of confusion is mixing “patent term extension” with “biosimilar exclusivity” rules. Even if a patent expires, biosimilar entry may still be constrained by:
- Additional patents in the same family or different families covering formulations, methods of use, or manufacturing.
- Regulatory exclusivity periods that delay approval even when patent rights are limited.
So the real-world “earliest possible entry” can depend more on the broader protection landscape than on one extended patent term.
What I need from you to answer with exact dates and citations
If you share any of the following, I can give a precise answer about whether and how the alemtuzumab patent term was extended:
- Jurisdiction (e.g., US or EU).
- Patent number(s) you mean.
- The product name and authorization (e.g., for which indication and which country).
- The company/brand you’re asking about (e.g., Campath/other brands).
Sources
No sources were provided with your question, so there are no citations to list.